{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T00:45:44Z","timestamp":1787013944375,"version":"build-2736575974"},"reference-count":54,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2013,10,22]],"date-time":"2013-10-22T00:00:00Z","timestamp":1382400000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/3.0\/"}],"content-domain":{"domain":["bjui-journals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["BJU International"],"published-print":{"date-parts":[[2014,3]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>\n                      <jats:list list-type=\"bullet\">\n                        <jats:list-item>\n                          <jats:p>\n                            To evaluate our clinical experience with percutaneous image\u2010guided radiofrequency ablation (\n                            <jats:styled-content style=\"fixed-case\">RFA<\/jats:styled-content>\n                            ) of 200 renal tumours in a large tertiary referral university institution.\n                          <\/jats:p>\n                        <\/jats:list-item>\n                      <\/jats:list>\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and Methods<\/jats:title>\n                    <jats:p>\n                      <jats:list list-type=\"bullet\">\n                        <jats:list-item>\n                          <jats:p>\n                            Image\u2010guided\n                            <jats:styled-content style=\"fixed-case\">RFA<\/jats:styled-content>\n                            (ultrasonography or computed tomography [\n                            <jats:styled-content style=\"fixed-case\">CT<\/jats:styled-content>\n                            ]) of 200 renal tumours in 165 patients from\n                            <jats:styled-content style=\"fixed-case\">J<\/jats:styled-content>\n                            une 2004 to 2012 was prospectively evaluated. Institutional Review Board approval was granted.\n                          <\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>\n                            The treatment response and technical success were defined by absence of contrast enhancement within the tumour on contrast enhanced\n                            <jats:styled-content style=\"fixed-case\">CT<\/jats:styled-content>\n                            or magnetic resonance imaging.\n                          <\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>\n                            Both major and minor complications, glomerular filtration rate (\n                            <jats:styled-content style=\"fixed-case\">GFR<\/jats:styled-content>\n                            ) before and after\n                            <jats:styled-content style=\"fixed-case\">RFA<\/jats:styled-content>\n                            , the management and outcomes of the complications, as well as oncological outcome were prospectively documented.\n                          <\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>\n                            Multivariate analysis was used to determine variables associated with major complications and also the percentage\n                            <jats:styled-content style=\"fixed-case\">GFR<\/jats:styled-content>\n                            change after\n                            <jats:styled-content style=\"fixed-case\">RFA<\/jats:styled-content>\n                            .\n                          <\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>\n                            The overall (\n                            <jats:styled-content style=\"fixed-case\">OS<\/jats:styled-content>\n                            ), 5\u2010year cancer\u2010specific (\n                            <jats:styled-content style=\"fixed-case\">CSS<\/jats:styled-content>\n                            ), local recurrence\u2010free (\n                            <jats:styled-content style=\"fixed-case\">LRFS<\/jats:styled-content>\n                            ) and metastasis\u2010free survival (\n                            <jats:styled-content style=\"fixed-case\">MFS<\/jats:styled-content>\n                            ) rates are presented using the\n                            <jats:styled-content style=\"fixed-case\">K<\/jats:styled-content>\n                            aplan\u2013\n                            <jats:styled-content style=\"fixed-case\">M<\/jats:styled-content>\n                            eier curves.\n                          <\/jats:p>\n                        <\/jats:list-item>\n                      <\/jats:list>\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      <jats:list list-type=\"bullet\">\n                        <jats:list-item>\n                          <jats:p>\n                            In all, 200 tumours were\n                            <jats:styled-content style=\"fixed-case\">RF<\/jats:styled-content>\n                            ablated with a mean (range) tumour size of 2.9 (1\u20135.6) cm and the mean (range) patient age was 67.7 (21\u201388.6) years with a mean follow\u2010up period of 46.1 months.\n                          <\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>\n                            The primary technical and overall technical success rate was 95.5% and 98.5%, respectively. Two independent predictors of successful\n                            <jats:styled-content style=\"fixed-case\">RFA<\/jats:styled-content>\n                            in a single sitting were tumour size (&lt;3\u2009cm) and exophytic location in multivariate logistic regression analysis.\n                          <\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>Major complications included ureteric injury (six patients), calyceal\u2010cutaneous fistula (one), acute tubular necrosis (one) and abscess (two). Two independent predictors of ureteric injury were central location and lower pole position.<\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>\n                            Within this cohort of patients, only four patients developed significant renal function deterioration i.e. &gt;25% decreased in\n                            <jats:styled-content style=\"fixed-case\">GFR<\/jats:styled-content>\n                            . In all, 161 (98%) patients of the 165 patients have preservation of renal function. Any change in renal function after\n                            <jats:styled-content style=\"fixed-case\">RFA<\/jats:styled-content>\n                            was not influenced by tumour factors or solitary kidney status.\n                          <\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>\n                            In our clinical series, this yielded a 5\u2010year\n                            <jats:styled-content style=\"fixed-case\">OS<\/jats:styled-content>\n                            ,\n                            <jats:styled-content style=\"fixed-case\">CSS<\/jats:styled-content>\n                            ,\n                            <jats:styled-content style=\"fixed-case\">LRFS<\/jats:styled-content>\n                            and\n                            <jats:styled-content style=\"fixed-case\">MFS<\/jats:styled-content>\n                            rates of 75.8%, 97.9%, 93.5% and 87.7% respectively.\n                          <\/jats:p>\n                        <\/jats:list-item>\n                      <\/jats:list>\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      <jats:list list-type=\"bullet\">\n                        <jats:list-item>\n                          <jats:p>\n                            Image\u2010guided\n                            <jats:styled-content style=\"fixed-case\">RFA<\/jats:styled-content>\n                            is a safe, nephron sparing and effective treatment for small renal cell carcinoma (RCC) tumours with a low rate of recurrence and has good 5\u2010year\n                            <jats:styled-content style=\"fixed-case\">CSS<\/jats:styled-content>\n                            and\n                            <jats:styled-content style=\"fixed-case\">MFS<\/jats:styled-content>\n                            rates.\n                          <\/jats:p>\n                        <\/jats:list-item>\n                      <\/jats:list>\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/bju.12349","type":"journal-article","created":{"date-parts":[[2013,7,2]],"date-time":"2013-07-02T10:11:10Z","timestamp":1372759870000},"page":"416-428","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":198,"title":["Radiofrequency ablation (\n                    <scp>RFA<\/scp>\n                    ) of renal cell carcinoma (\n                    <scp>RCC<\/scp>\n                    ): experience in 200 tumours"],"prefix":"10.1111","volume":"113","author":[{"given":"Tze M.","family":"Wah","sequence":"first","affiliation":[{"name":"Department of Diagnostic and Interventional Radiology Institute of Oncology, Leeds Teaching Hospitals Trust St. James's University Hospital  Leeds UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry C.","family":"Irving","sequence":"additional","affiliation":[{"name":"Department of Diagnostic and Interventional Radiology Institute of Oncology, Leeds Teaching Hospitals Trust St. James's University Hospital  Leeds UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walter","family":"Gregory","sequence":"additional","affiliation":[{"name":"Clinical Trials Research Unit (CTRU) University of Leeds  Leeds UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jon","family":"Cartledge","sequence":"additional","affiliation":[{"name":"Department of Urology St. James's University Hospital  Leeds UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian D.","family":"Joyce","sequence":"additional","affiliation":[{"name":"Department of Urology St. James's University Hospital  Leeds UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter J.","family":"Selby","sequence":"additional","affiliation":[{"name":"Leeds Institute of Molecular Medicine St. James's University Hospital  Leeds UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2013,10,22]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.3322\/canjclin.54.1.8"},{"key":"e_1_2_6_3_1","volume-title":"Cancer Statistics Registrations: Registrations of Cancer Diagnosed in 2008, England","author":"Office for National Statistics","year":"2010"},{"key":"e_1_2_6_4_1","unstructured":"Globocan 2008"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.2214\/ajr.175.4.1750945"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-4295(97)00506-2"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djj362"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2006.07.144"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(05)65640-6"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-4295(00)00655-5"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-4295(00)00534-3"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2008.09.053"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2008.04.033"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2010.06.032"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(06)70803-8"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2011.06.040"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(05)66066-1"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2007.08.156"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(01)63537-7"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(06)69302-1"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.25002"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2010.12.077"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1089\/end.2011.0179"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0033-8389(03)00074-5"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.2262012062"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.2214\/ajr.180.6.1801503"},{"key":"e_1_2_6_27_1","doi-asserted-by":"publisher","DOI":"10.2214\/ajr.163.3.8079852"},{"key":"e_1_2_6_28_1","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.2243011048"},{"key":"e_1_2_6_29_1","doi-asserted-by":"publisher","DOI":"10.1148\/radiology.217.3.r00dc39665"},{"key":"e_1_2_6_30_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00270-007-9090-x"},{"key":"e_1_2_6_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jvir.2008.04.005"},{"key":"e_1_2_6_32_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.RVI.0000175322.05225.0A"},{"key":"e_1_2_6_33_1","doi-asserted-by":"publisher","DOI":"10.2214\/ajr.181.5.1811315"},{"key":"e_1_2_6_34_1","doi-asserted-by":"publisher","DOI":"10.1148\/rg.272065083"},{"key":"e_1_2_6_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jvir.2008.06.006"},{"key":"e_1_2_6_36_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00270-007-9191-6"},{"key":"e_1_2_6_37_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.ju.0000162046.45024.2b"},{"key":"e_1_2_6_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2008.04.031"},{"key":"e_1_2_6_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2012.08.062"},{"key":"e_1_2_6_40_1","doi-asserted-by":"publisher","DOI":"10.2214\/ajr.185.1.01850064"},{"key":"e_1_2_6_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2004.12.011"},{"key":"e_1_2_6_42_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.sla.0000118565.21298.0a"},{"key":"e_1_2_6_43_1","doi-asserted-by":"publisher","DOI":"10.2214\/AJR.07.2258"},{"key":"e_1_2_6_44_1","doi-asserted-by":"publisher","DOI":"10.2214\/ajr.185.1.01850072"},{"key":"e_1_2_6_45_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa041031"},{"key":"e_1_2_6_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jvir.2011.09.002"},{"key":"e_1_2_6_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.crad.2009.11.007"},{"key":"e_1_2_6_48_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2009.08776.x"},{"key":"e_1_2_6_49_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jvir.2011.10.011"},{"key":"e_1_2_6_50_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(08)60604-7"},{"key":"e_1_2_6_51_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.23896"},{"key":"e_1_2_6_52_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2009.10.023"},{"key":"e_1_2_6_53_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2008.01.100"},{"key":"e_1_2_6_54_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2009.05.035"},{"key":"e_1_2_6_55_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2009.07.040"}],"container-title":["BJU International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbju.12349","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bjui-journals.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bju.12349","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T18:09:03Z","timestamp":1761761343000},"score":1,"resource":{"primary":{"URL":"https:\/\/bjui-journals.onlinelibrary.wiley.com\/doi\/10.1111\/bju.12349"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,10,22]]},"references-count":54,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014,3]]}},"alternative-id":["10.1111\/bju.12349"],"URL":"https:\/\/doi.org\/10.1111\/bju.12349","archive":["Portico"],"relation":{},"ISSN":["1464-4096","1464-410X"],"issn-type":[{"value":"1464-4096","type":"print"},{"value":"1464-410X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,10,22]]},"assertion":[{"value":"2013-10-22","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}